Urinary albumin-to-creatinine ratio (UACR) \>=500 and \< 5000 mg/g
Treatment with either angiotensin converting enzyme inhibitor or angiotensin II receptor blocker for at least three months prior to screening
Women of child-bearing potential using a highly effective birth control method must be willing to use the same method of contraception during the entire course of the study
You may not be if
Treatment with a PPARgamma agonist and/or PPARalpha agonist in the last 12 weeks screening
Prior intolerance to a TDZ or fibrate
Previous participation in a trial with aleglitazar
Diagnosis or history of other types of diabetes
Diagnosis or history of acute metabolic diabetic complications within the past 6 months
Known primary glomerulonephritis, secondary glomerulonephritis other than diabetic nephropathy or polycystic kidney disease
Diagnosed acute kidney injury or dialysis within 12 weeks prior to screening
Known secondary hypertension due to renal artery stenosis, primary aldosteronism, or pheochromocytoma
History of myocardial infarction or stroke in the past 12 weeks prior to screening
Symptomatic congestive heart failure NYHA class II-IV at baseline or heart failure leading to hospitalization within the 12 months prior to screening
Diagnosed and/or treated malignancy (except for treated cases of basal cell skin cancer, in situ carcinoma of the cervix, or in situ prostate cancer) within the past 5 years
Inadequate liver and hematological function
Chronic treatment with immunosuppressive therapy
Women who are pregnant, intending to become pregnant during the study period, currently lactating females, or women of child-bearing potential not using highly effective birth control methods
Clareo Health | A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)
